Eyenovia Reports Third Quarter 2020 Financial Results
Company to host conference call and webcast today, November 10, at 4:30pm ET NEW YORK,…
Company to host conference call and webcast today, November 10, at 4:30pm ET NEW YORK,…
PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian…
Pivotal Phase 3 PHALCON-EE trial enrollment expected to complete before year-end 2020; top-line results expected…
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for…
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage…
Third quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (“FDA”)…
– Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular…
TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent…
GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF)…
NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:…
PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG) today reported…
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical…
Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate…
– Updated clinical data from BIO89-100’s Phase 1b/2a NASH trial to be presented as a…
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level…
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical…
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading…